About Event

As the space distils the winning BCMA-targeted approaches, join this comprehensive forum of 80+ BCMA experts from large pharma, innovative biotech and research institutes. Don’t miss this opportunity to explore potentially practice-changing BCMA-targeted drugs that are shaking up the treatment paradigm for multiple myeloma patients. Whether you are developing an ADC, a CAR-T or a Bispecific for the BCMA target, this is the meeting for you.

New for 2022, we will be addressing differentiating your drug, multiple myeloma biology, toxicities and resistance mechanisms, as well as contextualizing where BCMA targeted therapies fit into the patient continuum of care with combinatorial and sequencing regimens to smartly improve the therapeutic outlook for patients.

What we covered?

24680 favicon

Understanding the broadening landscape of BCMA-targeted therapies across all modalities, differentiating drugs & forecasting the future & gaps of unmet need with Johnson & Johnson, Regeneron, CARsgen, Allogene & 2SeventyBio

24680 favicon

Explore progress in BCMA sequencing and how current experts are overcoming challenges of patient selection with Fred Hutchinson Cancer Research Center (FHCRC), Heidelberg University, National Cancer Institute, MD Anderson & Legend Biotech

24680 favicon

Unlock rationale and updates in combination strategy, addressing resistance & toxicities with Bristol-Myers Squibb, SpringWorks, Johnson & Johnson, University of Salamanca & Roswell Park Cancer Institute

24680 favicon

Delve into optimizing biomarker use & explore novel therapeutics in early development with Pfizer, Arcellx, Gracell Bio & more

24680 favicon

Network in person with your peers, ask your burning questions, build connections, and fully immerse yourself in the world of BCMA

“The meeting facilitates the cross pollination of ideas between scientists with a remarkable range of expertise connected by a shared commitment to improving the efficacy of BCMA targeting strategies.” 

Damian Green, Associate Professor, Deputy Directory for Translational Myeloma Research, Fred Hutchinson Cancer Research Center & University of Washington